Nxera Pharma Earns $10M Milestone as Neurocrine Wins FDA Acceptance for Alzheimer’s Phase 2 Study
Tokyo, Japan and Cambridge, UK — August 26, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences...
Nxera Pharma
Advertisement
Nxera Pharma Advances Schizophrenia Drug to Phase 2
TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....
Nxera Pharma FY2025 Results Signal Pipeline Expansion
TOKYO, Feb. 13, 2026 — Nxera Pharma Co., Ltd. reported its consolidated financial and operational results for FY2025, outlining...
Nxera Pharma Restructures to Accelerate Profitability and R&D Innovation
Dateline – November 17 2025 | Tokyo, Japan & Cambridge/London, UK Nxera Pharma announced a major restructuring initiative aimed...
Corbus Pharmaceuticals Raises $75M to Advance Oncology and Obesity Pipeline
Norwood, Massachusetts – October 31, 2025 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), an oncology and obesity-focused biotechnology company,...
Advertisements
Nxera Expands Asian Manufacturing for QUVIVIQ to Boost Supply and Profitability
TOKYO, Japan – October 31, 2025 — Nxera Pharma Co., Ltd. announced that its subsidiary, Nxera Pharma Japan, has...
Advertisement
